# Less soreness doesn't always mean the joint has changed *Plain Evidence for Joint Regeneration Peoria* > Joint regeneration Peoria facts on soreness, movement, X-rays and the limits of claims about worn joints. Let the exam guide what you try next. An X-ray can show wear, but it can't measure your soreness. How you walk, sleep and use the joint also matters. You don't need to choose treatment from the X-ray alone. The ache may change while the X-ray stays the same. A busy week can hurt more than a quiet week. Feeling better and rebuilding joint tissue are different results. One doesn't prove the other happened. ## Less soreness matters even when the joint hasn't grown back Less soreness can make stairs, sleep and errands easier. Cartilage is the smooth layer covering bone ends inside a joint. Feeling better doesn't prove that worn cartilage became new again. Your daily goal can stay as simple as an easier walk. Results from prepared-blood care don't all agree. One careful study found no more relief than saltwater placed in the joint. Other studies reported more relief than other common joint shots. You'll judge relief better by checking the same stairs or walk afterward. You deserve that plain answer before spending money. ## A treatment claim needs to say what may feel different At QC Kinetix, medical providers—trained clinic staff—offer platelet-rich plasma (PRP), a regenerative treatment made by spinning your blood before the platelet-rich part goes into the joint. The term describes the clinic care, not a promise of new tissue. Relief may be the result being discussed. It shouldn't be confused with rebuilding a worn joint. Ask what may change in your normal day. The answer could be easier sleep, longer walks or fewer hard stairs. Ask how long that change might last. If the answer isn't clear, waiting is reasonable. ## Sources 1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 5. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 6. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. ## A Peoria visit can put choices and costs in writing The clinic is at 13128 N. 94th Dr., Suite 205. Trained clinic staff can examine the sore joint and discuss available care. You'll have time to ask about costs, visits and likely relief. Bring an old X-ray and medicine names if they're handy. The office can be reached at (602) 837-PAIN. You can wait to choose until the answers make sense. Book an appointment: --- Practical help for a sore joint Plain help with joint soreness, relief at home, medical visits and care choices in Peoria, Arizona. Plain Peoria help with joint soreness, care at home, clinic visits and local travel. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria location, and the owners may benefit when a reader books a consultation. © 2026 Peoria Joint Ledger. General health education, not personal medical advice; discuss your own joint, risks and options with a qualified clinician.